James Noble

This profile gathers the share dealings of James Noble across 3 companies, led by GW Pharmaceuticals PLC, Adaptimmune Therapeutics PLC and Curagen Corp. We count 15 filings; the first trade dates from 8 May 2007 and the latest from 5 May 2021.

Market trades split into 1 purchase (€42k) and 8 sales (€6.6M). The net balance comes to €6.6M on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 3 option exercises.

The newest entry dates from 7 May 2021: a transaction, in GW Pharmaceuticals PLC. The last insider purchase was made public on 9 May 2007, 7,108 days ago. Typically, a trade is published a median of 5 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.